Before we delve into what the studies actually show, it's worth stating something important upfront. This article does not contain a „how much to take,” „how many mcg per injection,” or „how often to inject” guide for the self-administration of CJC-1295 and Ipamorelin. This is not an oversight – these compounds are not approved for human use, there is no established consumer dosing protocol, and any such guidance would go beyond what a responsible, evidence-based source should offer without medical supervision. Instead, the following provides a factual overview of doses actually used in controlled clinical and laboratory studies, along with an explanation of why this type of research dosing cannot be safely translated into a personal dosing schedule.
What is the standard dosage of CJC-1295 and Ipamorelin?
There is no standard, medically established dosage for CJC-1295, ipamorelin, or their combination. This is because neither of these compounds has gone through the full clinical trial process required to determine an approved, safe dosing regimen for any population. What exists are specific doses used by researchers in early-phase pharmacological studies, administered in controlled clinical settings under medical supervision. These figures describe what was tested in a research context – they are not recommendations for personal use.
In the main human study of CJC-1295, healthy adult volunteers received single, escalating subcutaneous doses. Researchers identified doses of 30 and 60 micrograms per kilogram of body weight as inducing a sustained, dose-dependent hormone increase with the best tolerance profile in that study. Higher doses were also tested as part of the escalating-dose study design, and multiple-dosing regimens included two or three administrations weekly or bi-weekly [1]. For ipamorelin, a separate pharmacokinetic study in humans utilized intravenous infusions at five different dose levels. It demonstrated that the concentration required for half-maximal growth hormone stimulation was 214 nanomoles per liter, with dose-proportional pharmacokinetics observed within the studied range [2].
These numbers derive from clinical trial protocols designed by scientists to investigate hormonal response curves under medical supervision, with real-time monitoring for adverse events. They are not equivalent to a dosing guide for home use and should not be treated as such, as these studies did not test repeated self-administration over weeks or months in unmonitored settings. No published study has tested CJC-1295 and ipamorelin administered together as a combination in humans at all.
Dosage of CJC-1295 and Ipamorelin for bodybuilding
There are no clinical studies establishing the dosing of CJC-1295, ipamorelin, or their combination for bodybuilding, muscle growth, or physique purposes. This article will also not provide injection frequencies, weekly schedules, or mcg-based recommendations for this purpose. This gap is not a minor oversight. Reviews of injectable peptide use in sports and orthopedic medicine have specifically highlighted this as a serious problem, noting that information regarding indications, dosing, frequency, and duration of treatment with these compounds remains unknown—even as their popularity among general consumers and the bodybuilding community has significantly increased [3].
A separate 2026 review of peptide use in recreational and professional sports went further. It described the supply chain for these products as largely unregulated, with documented risks of contamination and mislabeling. It also specifically noted that supra-physiological or combined dosing protocols common in bodybuilding communities had not been studied in existing controlled clinical trials, which instead used lower, carefully monitored doses of a therapeutic nature [4].
Taking this into consideration, any specific bodybuilding dosage numbers circulating on the internet – regardless of whether they are presented as „typical,” „standard,” or „beginner” doses – do not come from peer-reviewed clinical evidence and should not be treated as validated or safe.
How to dose CJC-1295 with DAC compared to CJC-1295 without DAC
Available clinical dosing data pertain specifically to the DAC-conjugated, long-acting form of CJC-1295. There is no equivalent published human dosing study for the non-DAC version („Mod GRF 1-29") identified in the peer-reviewed literature reviewed for this article. In the aforementioned human study, the DAC-conjugated form was tested in single doses—with doses of 30 and 60 micrograms per kilogram identified as eliciting sustained, well-tolerated hormonal responses—as well as in multiple dosing regimens spaced weekly or bi-weekly. This reflects the compound's long half-life of approximately 5.8–8.1 days, meaning less frequent dosing was sufficient to maintain elevated hormone levels over time [1].
Since the non-DAC form lacks the albumin binding mechanism responsible for this prolonged action, one might expect—based on its shorter presumed half-life and structural similarity to endogenous GHRH—that it would require a different, likely more frequent, dosing regimen to elicit a comparably sustained effect. This, however, is a conclusion based on chemistry and pharmacokinetic principles, rather than a finding confirmed by a dedicated human dosing study of the non-DAC form.
No published studies have been identified that establish a specific, validated dosing regimen for the DAC-free form, whether used alone or in combination with ipamorelin. This means that any specific frequency or amount provided for this combination is not something this article can responsibly deliver.
Why don't we provide a practical dosage recommendation?
Readers looking for specific microgram, milliliter, or injection schedule details may find the absence of this information frustrating. However, providing it would be irresponsible given the current state of evidence. CJC-1295 and Ipamorelin are not approved by any major regulatory body for human use. There is no clinical trial establishing a safe or effective self-administration protocol for muscle growth, fat loss, or anti-aging purposes. And the doses used in the studies referenced above were administered by clinicians under monitored conditions specifically to examine hormonal response – not to model long-term consumer use.
Reviews encompassing this class of peptides consistently identify unknown dosing, unregulated product quality, and a lack of long-term human safety data as active, unresolved issues—rather than established details that can be simply looked up [3], [4]. Any individual considering the use of these compounds should understand that „dosing tables” circulating in commercial or informal contexts do not originate from peer-reviewed clinical literature and have not been validated for safety or efficacy.
Disclaimer
This content is for educational purposes only and is not medical advice, dosage guidance, or therapeutic recommendation. CJC-1295 and ipamorelin are research compounds and are not approved by the FDA or European Medicines Agency for any medical use, whether used individually or in combination. The dosing information presented here reflects amounts used in controlled clinical and laboratory research settings under medical supervision and is not intended to guide or encourage self-administration. There is no validated consumer dosing protocol for either of these compounds.
References
Teichman, S. L., Neale, A., Lawrence, B., Gagnon, C., Castaigne, J. P., & Frohman, L. A. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology & Metabolism, 91(3), 799–805. https://doi.org/10.1210/jc.2005-1536
Gobburu, J. V., Agersø, H., Jusko, W. J., & Ynddal, L. (1999). Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharmaceutical Research, 16(9), 1412–1416. https://doi.org/10.1023/a:1018955126402
[3] Mayfield, C. K., Bolia, I. K., Feingold, C. L., Lin, E. H., Liu, J. N., Hatch, G. F. R., Gamradt, S. C., & Weber, A. E. (2026). Injectable peptide therapy: A primer for orthopaedic and sports medicine physicians. American Journal of Sports Medicine, 54(1), 223–229. https://doi.org/10.1177/03635465251357593
[4] Coutinho, L. F. D., De Oliveira Neves, L. F., & Camilo, R. P. (2026). A new era of doping? Use of peptide and peptide-analog drugs in recreational and professional sport and bodybuilding: A critical review. Journal of Sports Medicine and Physical Fitness, 66(7), 880–885. https://doi.org/10.23736/S0022-4707.26.17773-1